Here, we summarize the clinical data on a number of agents being studied as maintenance/preemptive therapies after allo-HSCT in AML focusing mainly on TKIs (FLT3 inhibitors) and HMAs (azacitidine and decitabine). Here, FLT3 is linked to acute myeloid leukemia.